Novavax (Germany) Performance
| NVV1 Stock | EUR 8.38 0.53 5.95% |
The company secures a Beta (Market Risk) of 1.27, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Novavax will likely underperform. At this point, Novavax has a negative expected return of -0.19%. Please make sure to verify Novavax's kurtosis, daily balance of power, and the relationship between the skewness and accumulation distribution , to decide if Novavax performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Novavax has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 648.7 M | |
| Total Cashflows From Investing Activities | 100.2 M |
Novavax |
Novavax Relative Risk vs. Return Landscape
If you would invest 1,046 in Novavax on August 29, 2024 and sell it today you would lose (208.00) from holding Novavax or give up 19.89% of portfolio value over 90 days. Novavax is producing return of less than zero assuming 5.6346% volatility of returns over the 90 days investment horizon. Simply put, 50% of all stocks have less volatile historical return distribution than Novavax, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Novavax Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Novavax's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Novavax, and traders can use it to determine the average amount a Novavax's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0329
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NVV1 |
Estimated Market Risk
| 5.63 actual daily | 50 50% of assets are less volatile |
Expected Return
| -0.19 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Novavax is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Novavax by adding Novavax to a well-diversified portfolio.
Novavax Fundamentals Growth
Novavax Stock prices reflect investors' perceptions of the future prospects and financial health of Novavax, and Novavax fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Novavax Stock performance.
| Return On Equity | -8.98 | |||
| Return On Asset | -0.32 | |||
| Profit Margin | (0.72) % | |||
| Operating Margin | (0.66) % | |||
| Current Valuation | 484 M | |||
| Shares Outstanding | 85 M | |||
| Price To Book | 72.32 X | |||
| Price To Sales | 0.45 X | |||
| Revenue | 1.15 B | |||
| EBITDA | (1.68 B) | |||
| Cash And Equivalents | 1.57 B | |||
| Cash Per Share | 20.11 X | |||
| Total Debt | 323.46 M | |||
| Debt To Equity | 8.24 % | |||
| Book Value Per Share | (7.21) X | |||
| Cash Flow From Operations | 322.95 M | |||
| Earnings Per Share | (15.18) X | |||
| Total Asset | 2.58 B | |||
About Novavax Performance
By analyzing Novavax's fundamental ratios, stakeholders can gain valuable insights into Novavax's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Novavax has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Novavax has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. NOVAVAX INC operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 1541 people.Things to note about Novavax performance evaluation
Checking the ongoing alerts about Novavax for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Novavax help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Novavax generated a negative expected return over the last 90 days | |
| Novavax has high historical volatility and very poor performance | |
| Novavax has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 1.15 B. Net Loss for the year was (1.74 B) with loss before overhead, payroll, taxes, and interest of (1.39 B). | |
| About 62.0% of the company shares are owned by institutional investors |
- Analyzing Novavax's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Novavax's stock is overvalued or undervalued compared to its peers.
- Examining Novavax's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Novavax's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Novavax's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Novavax's stock. These opinions can provide insight into Novavax's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Novavax Stock analysis
When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |